# US 2018/0021299 A9 · Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021299 A9
- Document ID: US20180021299A9
- Status: Published application
- Kind: A9
- Application number: 12/041,188
- Filed: 2008-03-03
- Published: 2018-01-25
- Earliest claimed: 2003-04-08
- Assignees: Dart NeuroScience (Cayman) Ltd.
- Inventors: Thomas M. Hallam; Tim Tully; Rusiko Bourtchouladze
- Web page: https://patentgrep.com/patent/US20180021299A9

## CPC

- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/4418: having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A61P 25/00: Drugs for disorders of the nervous system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides methods of improving cognitive and motor deficits associated with central nervous system (CNS) disorder or condition in an animal. The methods comprise a general administration of phosphodiesterase 4 inhibitors and optionally training the animal under conditions sufficient to produce an improvement in performance.

## Claims

### Claim at position 1

1-23. (canceled)

### Claim 24

A method for improving a motor deficit associated with a central nervous system (CNS) disorder or condition in an animal comprising treating the animal with a phosphodiesterase 4 (PDE4) inhibitor in the absence of formal cognitive training.

### Claim 25 (depends on 24)

The method of claim 24 wherein said animal is a human.

### Claim 26 (depends on 24)

The method of claim 24 wherein the phosphodiesterase 4 (PDE4) inhibitor is selected from rolipram or compounds of Formula I:
wherein “Me” means “methyl” and “cPent” means “cyclopentyl” and enantimers and mixtures thereof.

### Claim 27 (depends on 26)

The method of claim 26 wherein the phosphodiesterase 4 (PDE4) inhibitor comprises the structure:
wherein “Me” means “methyl” and “cPent” means “cyclopentyl”.

### Claim 28

A method for providing sustained improvement in a motor deficit associated with a central nervous system (CNS) disorder or condition in an animal comprising administering to the animal a phosphodiesterase 4 (PDE4) inhibitor; and detecting said sustained improvement.

### Claim 29 (depends on 28)

The method of claim 28, further comprising the step of training the animal under conditions sufficient to produce an improvement in performance of a particular cognitive task.

### Claim 30 (depends on 29)

The method of claim 29, wherein a performance gain is achieved relative to the performance of said cognitive task achieved by training alone.

### Claim 31 (depends on 29)

The method of claim 29 wherein the training comprises multiple training sessions.

### Claim 32 (depends on 29)

The method of claim 29 wherein said phosphodiesterase 4 inhibitor is administered before and during each training session.

### Claim 33 (depends on 29)

The method of claim 29 wherein said phosphodiesterase 4 inhibitor is administered after each training session.
